Mediwound Ltd
MDWD
View Detailed Chart
18.620USD
-0.150-0.80%
Close 12/22, 16:00（ET）Quotes delayed by 15 min
238.74MMarket Cap
LossP/E TTM
Intraday
1m
30m
1h
D
W
M
D
Today
-0.80%
5 Days
-2.26%
1 Month
+9.14%
6 Months
-2.46%
Year to Date
+4.61%
1 Year
+12.92%
View Detailed Chart
TradingKey Stock Score of Mediwound Ltd
Currency: USD Updated: 2025-12-22Key Insights
Mediwound Ltd's fundamentals are relatively very healthy, and its growth potential is high.Its valuation is considered fairly valued, ranking 78/158 in the Pharmaceuticals industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 31.50.In the medium term, the stock price is expected to remain stable.Despite an average stock market performance over the past month, the company shows strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Mediwound Ltd's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Analyst Rating
Based on
6
analysts
Buy
Current Rating
31.500
Target Price
+70.18%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Mediwound Ltd Highlights
StrengthsRisks
Mediwound Ltd is an Israel-based biopharmaceutical company that develops, manufactures and commercializes novel, cost effective, bio-therapeutic solutions for tissue repair and regeneration. Company's portfolio is focused on next-generation protein-based therapies for burn and wound care and tissue repair and includes products such as, NexoBrid, a concentrate of proteolytic enzymes enriched in bromelain, which is an easy to use, topically-applied product that removes eschar in four hours without harming the surrounding healthy tissues.; EscharEx biological drug candidate for the debridement of chronic and other hard-to-heal wounds; MW005 a topically applied biological drug candidate for the treatment of non-melanoma skin cancers, based on the same API of NexoBrid and EscharEx products, a concentrate of proteolytic enzymes enriched in bromelain.
Growing
The company is in a growing phase, with the latest annual income totaling USD 20.22M.
High Profit Growth
The company's net income leads the industry, with the latest annual income totaling USD 20.22M.
Undervalued
The company’s latest PE is -10.07, at a low 3-year percentile range.
Institutional Buying
The latest institutional holdings are 5.72M shares, increasing 6.41% quarter-over-quarter.
Held by Invesco
Star Investor Invesco holds 3.98K shares of this stock.
Higher Market Activity
The company has more investor interest, with a 20-day turnover ratio of 0.19.
Mediwound Ltd News
More news coming soon, stay tuned...
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
Mediwound Ltd Info
Mediwound Ltd is an Israel-based biopharmaceutical company that develops, manufactures and commercializes novel, cost effective, bio-therapeutic solutions for tissue repair and regeneration. Company's portfolio is focused on next-generation protein-based therapies for burn and wound care and tissue repair and includes products such as, NexoBrid, a concentrate of proteolytic enzymes enriched in bromelain, which is an easy to use, topically-applied product that removes eschar in four hours without harming the surrounding healthy tissues.; EscharEx biological drug candidate for the debridement of chronic and other hard-to-heal wounds; MW005 a topically applied biological drug candidate for the treatment of non-melanoma skin cancers, based on the same API of NexoBrid and EscharEx products, a concentrate of proteolytic enzymes enriched in bromelain.
Ticker SymbolMDWD
CompanyMediwound Ltd
CEOGonen (Ofer)
Websitehttps://www.mediwound.com/
FAQs
What is the current price of Mediwound Ltd (MDWD)?
The current price of Mediwound Ltd (MDWD) is 18.620.
What is the symbol of Mediwound Ltd?
The ticker symbol of Mediwound Ltd is MDWD.
What is the 52-week high of Mediwound Ltd?
The 52-week high of Mediwound Ltd is 22.505.
What is the 52-week low of Mediwound Ltd?
The 52-week low of Mediwound Ltd is 14.140.
What is the market capitalization of Mediwound Ltd?
The market capitalization of Mediwound Ltd is 238.74M.
What is the net income of Mediwound Ltd?
The net income of Mediwound Ltd is -30.22M.
Is Mediwound Ltd (MDWD) currently rated as Buy, Hold, or Sell?
According to analysts, Mediwound Ltd (MDWD) has an overall rating of Buy, with a price target of 31.500.
What is the Earnings Per Share (EPS TTM) of Mediwound Ltd (MDWD)?
The Earnings Per Share (EPS TTM) of Mediwound Ltd (MDWD) is -1.850.
Related Instruments
+0.44%
+0.43%
+0.45%
+0.21%
+0.60%
+3.60%
+1.22%
+0.04%
-0.10%
+0.10%
-0.31%
+0.90%
+0.82%
-0.25%
-0.02%
+0.71%
+1.48%
0.00%
+1.25%
+1.87%
